KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Free Cash Flow (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Free Cash Flow data on record, last reported at -$52.7 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 232.08% year-over-year to -$52.7 million; the TTM value through Dec 2025 reached $105.4 million, down 32.92%, while the annual FY2025 figure was $105.1 million, 33.11% down from the prior year.
  • Free Cash Flow reached -$52.7 million in Q4 2025 per ACAD's latest filing, down from $73.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $85.4 million in Q4 2023 and bottomed at -$76.3 million in Q1 2022.
  • Average Free Cash Flow over 5 years is $1.9 million, with a median of -$6.9 million recorded in 2022.
  • The widest YoY moves for Free Cash Flow: up 457.97% in 2023, down 8009.35% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$23.1 million in 2021, then dropped by 3.17% to -$23.9 million in 2022, then soared by 457.97% to $85.4 million in 2023, then crashed by 53.24% to $39.9 million in 2024, then plummeted by 232.08% to -$52.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$52.7 million in Q4 2025, $73.9 million in Q3 2025, and $64.0 million in Q2 2025.